October 2026
Largest Life Sciences Tools Public Companies
Benchmark revenue and EBITDA valuation multiples for public comps like
Merck KGaA, Illumina, Sartorius, Demant and Bio-Techne.
 | Merck KGaA operates in three main segments: life science, electronics, and healthcare. The life science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck family publicly sold part of the company, resulting in the current 30% public ownership of the firm. | $162 | +23% | $71B | $81B | 3.4x | 15.7x | ||
 | Illumina is a genomics company headquartered in San Diego, California, that develops and sells DNA sequencing and array-based systems for research, clinical and applied markets. It was incorporated in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik and Mark Chee, and its shares trade on the Nasdaq under the symbol ILMN. Its NovaSeq, NextSeq and MiSeq sequencers and microarrays are bought by genomic research centers, pharmaceutical companies, academic institutions and clinical laboratories. Revenue comes from instrument sales and from the consumables and services used with an installed base of about 21,000 systems in 165 countries. Fiscal 2025 revenue was $4.34 billion, flat on 2024, with GAAP net income of $850 million, and the company has about 8,600 employees. It acquired the cancer-detection company GRAIL in 2021 and completed its spin-off in June 2024, keeping a 14.5% minority stake. In January 2025 it invested $20 million in Truveta alongside Regeneron to support the Truveta Genome Project. | $263 | +113% | $40B | $41B | 9.4x | 28.9x | ||
| Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%. | $231 | -16% | $18B | $24B | 5.9x | 22.9x | ||
 | Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe. | $54 | +62% | $11B | $14B | 4.1x | 18.7x | ||
| Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%. | $72 | +16% | $11B | $11B | 9.4x | 33.2x | ||
| 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China). | $70 | +421% | $9.1B | $8.6B | 13.4x | (534.7x) | ||
| BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response. | $101 | -- | $4.8B | $4.4B | 14.3x | 362.9x | ||
| Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). | $24 | +38% | $3.8B | $3.9B | 14.1x | (99.2x) | ||
| InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States. | $5 | -- | $2.9B | $2.3B | 41.2x | (6.6x) | ||
 | Oxford Nanopore Technologies PLC is involved in researching, developing, manufacturing and commercializing deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that provides rich data, is fast, accessible and easy to use, and which allows the real-time analysis of DNA or RNA. It has developed and brought to market a new generation molecular sensing platform based on nanopores. The first application is DNA/RNA sequencing and the platform is also being developed for the analysis of proteins and metabolites. It operates in single segment of providing products and services related to the sale and use of its nanopore-based sensing technology. Geographically its operations are spread across EMES, AMR, and APAC. | $3 | +48% | $2.6B | $2.4B | 8.1x | (18.3x) | ||
 | Bloomage BioTechnology Corp Ltd manufactures and sells a variety of chemicals and chemical-based products, typically made from hyaluronic acid or sodium hyaluronic acid. The company's products include raw materials, medical products, functional skincare, and functional foods. Raw materials, mainly hyaluronic acid, are used in pharmaceuticals, medical devices, cosmetics, and food. Medical products span beauty and therapeutic uses, such as viscoelastics, lubricants, fillers, and skin protectors. Skincare items include lotions, creams, and masks, while functional foods feature hyaluronic acid drinks and supplements. | $5 | -33% | $2.5B | $2.4B | 3.7x | 22.8x | ||
| GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis. | $4 | +70% | $1.8B | $1.6B | 13.7x | 43.8x | ||
| Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. | $16 | +65% | $1.7B | $1.5B | 21.9x | (19.5x) | ||
 | Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others. | $4 | -43% | $1.7B | $1.6B | 4.2x | 17.9x | ||
| Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials. | $3 | +26% | $1.7B | $1.4B | 6.7x | 77.4x | ||
| Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery. | $13 | -- | $1.6B | $1.2B | ||||
| Suzhou Sepax Technologies Co Ltd is engaged in the Research, development and produce liquid chromatography materials for drug analysis, detection, separation and purification. | $4 | +32% | $1.5B | $1.5B | ||||
| Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. | $9 | +100% | $1.5B | $1.3B | ||||
| Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories. | $2 | -23% | $1.4B | $1B | ||||
 | SEEGENE Inc is engaged in the healthcare sector. The Korean firm specializes in developing upgraded technology for accurate diagnosis of various diseases. Its products include pathogen inspection solutions such as respiratory, gastrointestinal, tuberculosis and meningitis pathogens. | $29 | +61% | $1.3B | $960M | ||||
| Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes. | $3 | -25% | $1.2B | $959M | ||||
| CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas. | $17 | +84% | $861M | $742M | ||||
| Bide Pharmatech Co Ltd is engaged in the research and development, design, production and sales of drug molecular building blocks. | $9 | -17% | $821M | $688M | ||||
| OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation. | $5 | +203% | $683M | $650M | ||||
| Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific. | $2 | -21% | $570M | $1B | ||||
| Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006. | $8 | -- | $417M | $138M | ||||
| Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea. | $1 | -3% | $391M | $386M | ||||
| Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States. | $7 | +29% | $365M | $375M | ||||
| Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis. | $3 | +99% | $337M | $281M | ||||
| Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. | $1 | -49% | $239M | $130M | ||||
| Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives. Geographically, it operates in UK, North America, Europe, and Asia and Rest of World. | $3 | +23% | $231M | $223M | ||||
| Genomictree Inc is a molecular diagnostic company. It is engaged in developing technologies that satisfies the unmet needs of the healthcare market. | $7 | -51% | $177M | $118M | ||||
 | Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World. | $0 | +23% | $165M | $162M | ||||
| Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others. | $2 | -9% | $151M | $141M | ||||
 | Vitrafy Life Sciences Ltd is the research, development and commercialisation of its integrated cryopreservation solution. This includes cryopreservation medical devices (freezer, thawer and packaging solutions), Life Chain integrated software system, and services for application areas in human health and animal reproduction. The group has one operating segment. The company's solutions are LifeChain TM, and Guardion TM. LifeChain TM is the nexus of modern cryopreservation, an intelligent platform unifying data-driven optimization, world-wide logistics, and proprietary algorithms to create bespoke freeze curves. Guardion TM rapidly freezes T-cells in under four minutes while maintaining post-thaw quality rivaling fresh controls. | $2 | +93% | $144M | $115M | ||||
| SDI Group PLC designs and manufactures scientific and technology products for use by the life science, healthcare, astronomy, consumer manufacturing, and art conservation markets through Synoptics, the Artemis, the Opus instruments, and Astles Control systems brands. The Digital Imaging segment incorporates the Synoptics brands Syngene, Synbiosis, Synoptics Health and Fistreem, the Atik brands Atik Cameras, Opus, and Quantum Scientific Imaging, and the Graticules Optics business. The Sensors & Control segment combines Sentek, Astles Control Systems, Applied Thermal Control, Thermal Exchange, MPB Industries, and Chell Instruments businesses. It operates in the UK, Europe, America, Rest of Asia, and Rest of the world segments. It derives majority of its revenues from the United Kingdom. | $1 | +15% | $133M | $175M | ||||
| Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. | $9 | -78% | $131M | $58M | ||||
| Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country. | $24 | -11% | $125M | $118M | ||||
| 4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States. | $7 | -33% | $108M | $91M | ||||
 | ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world. | $2 | -30% | $102M | $76M | ||||
| Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. | $3 | -51% | $96M | $81M | ||||
| Curiosis Inc develops, manufactures, and supplies bioresearch equipment, laboratory automation products, and medical devices designed to support laboratory automation and life science research. The company’s product portfolio encompasses high performance cell imaging instrumentation, cell counting and isolation systems, digital pathology platforms, colony picking robots, and related lab automation infrastructure. | $6 | -- | $93M | $82M | ||||
| M1 Aesthetics AG, formerly HAEMATO AG, is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany. | $14 | -- | $71M | $97M | ||||
| iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business. | $2 | -9% | $65M | $41M | ||||
| Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient’s stem cells to regenerate and restore function to damaged organs. | $2 | +15% | $45M | $45M | ||||
 | Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds and monoclonal antibodies and service laboratory operations. | $2 | -32% | $37M | $35M | ||||
| AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP. | $0 | 0% | $34M | $28M | ||||
 | Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others. | $0 | +14% | $32M | $29M | ||||
 | Genoway SA specializes in genetic designs to serve genetically modified (GM) mice, rat and cell lines for the biopharmaceutical industries and research industries. | $2 | -24% | $30M | $43M | ||||
 | LSL Pharma Group Inc integrated pharmaceutical company specializing in the development, manufacture and distribution of high-quality natural health products and dietary supplements in solid dosage forms as well as high quality sterile ophthalmic pharmaceutical products. | $0 | -16% | $27M | $62M | ||||
| Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and various biomedical applications. The company's product includes Gemini and Saliva tests. | $0 | -- | $24M | $25M | ||||
| Microba Life Sciences is an Australian precision microbiome company based in Brisbane that sells clinical gut microbiome tests and supplements and holds a pipeline of microbiome-based therapeutic candidates. It was founded in 2017 as a University of Queensland spin-out by Professors Gene Tyson and Philip Hugenholtz and listed on the Australian Securities Exchange on 5 April 2022. Its main product, MetaXplore, is a gastrointestinal test sold to clinicians in Australia and the United Kingdom, where it bought the Invivo Healthcare testing and supplements business in December 2023. Group revenue was A$15.7 million in the year to June 2025, up 30 per cent, and the net loss was A$14.9 million. Sonic Healthcare is its largest shareholder and a distribution partner for its tests. Microba transferred its research services unit to Clinical Microbiomics in late 2024 and paused internal research and development in the 2025 financial year to look for partners for its therapeutic assets. In 2026 it agreed commercial terms for a proposed all-scrip merger with Genetic Signatures. | $0 | -41% | $22M | $19M | ||||
 | Helyx Industries is an Italian molecular biology and diagnostics company, formerly named Ulisse BioMed, with corporate offices in Udine and research and manufacturing laboratories in Trieste. It was founded in 2015 by a group of researchers and is listed on Euronext Growth Milan. The group is organised in three divisions, Hyris, Vytro and Mytho, which cover PCR and next-generation sequencing solutions and a proprietary platform for molecular biology. Hyris, which joined the group in December 2023 through a reverse take-over, sells distributed qPCR products and has won public tenders in Spain and Italy. In 2026 the company was granted a United States patent for its deep multiplexing technology. Its market capitalisation was about EUR 20 million, with 26,444,787 shares in issue. | $1 | -32% | $21M | $20M | ||||
| Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia. | $3 | -- | $19M | $13M | ||||
| Pathkey.AI Ltd is engaged in the development of its digital tools that improve clinical trials, healthcare experience for patients, deliver deep market insights from social media data, and improve the efficiency and value of the clinical research process. It invests in research and develops technologies as well as provides digital tools and insights services to healthcare, wellness, and science technology-focused clients. The group's main revenue streams are Retainer revenue and Project revenue. | $0 | +13% | $19M | $16M | ||||
| Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx. | $0 | -64% | $13M | $11M | ||||
| Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. | $0 | -79% | $9M | $12M | ||||
| AcouSort AB is a company that specializes in products and solutions for the automated preparation of biological samples for researchers and life science companies. Its technology is based on using ultrasound to isolate, separate, or trap microscopic particles such as blood cells, bacteria, or extracellular vesicles in microfluidic channels. The company's products include AcouTrap, AcouWash, and AcouPlasma. | $0 | +9% | $7M | $6M | ||||
| Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine. | $3 | +105% | $4M | $4M | ||||
| Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company’s drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. | $1 | -- | $3M | $3M | ||||
| GenIP PLC is engaged in Generative Artificial Intelligence (GenAI), and empowers organizations to evaluate and commercialize technology discoveries through two distinct to providing bespoke enhanced research reports assessing the market potential for new technological innovations by using the GenAI-driven proprietary software, InventionEvaluator, and providing executive recruitment services to match technology organizations with experienced executives and business leaders using the GenAI-driven proprietary software, Vortechs. Its operating segments are Invention Evaluator and Vortechs. It generates the majority of its revenue from the Invention Evaluator segment. | $0 | -89% | $902K | $489K | ||||
| Median | $3 | +4% | $231M | $162M | 8.3x | (1.7x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.